Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 146Small Cell Lung Carcinoma 146Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 86Head and Neck Neoplasms 80Endometrial Neoplasms 77Uterine Cervical Neoplasms 72Esophageal Neoplasms 72Adenocarcinoma of Lung 71Neuroblastoma 55Central Nervous System Neoplasms 53Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Carboplatin × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡